SANTA CLARA, California, Feb. 25, 2019
Establishment of parallel workflows vital to gain regulatory approvals for the use of artificial intelligence capabilities in digital pathology, finds Frost & Sullivan
SANTA CLARA, California, Feb. 25, 2019 /PRNewswire/ -- Over the next decade, there will be a shift in digital pathology and artificial intelligence (AI) applications from the pharmaceutical sector to clinical diagnostics. Once they are established as primary and secondary diagnostic tools, clinicians will be able to decrease turnaround time, prioritize critical cases, and improve overall patient outcomes. However, for AI tools to gain regulatory approval for primary diagnosis in digital pathology, it is imperative to adopt a parallel workflow to showcase the superior benefits of pathology diagnoses that amass data.
"AI has the potential to analyze big data and find patterns and insights that could enhance patient outcomes in the field of pathology," said Deepak Jayakumar, Senior Research Analyst, TechVision. "It can serve as a supplementary or a validation tool in imaging analytics for pathologists and help process more slides in a shorter duration. So far, AI-based medical diagnostic tools like OsteoDetect have already been approved for use by the FDA for the detection of distal radius fracture. Furthermore, AI-powered tools can better identify skin lesions and the presence of invasive breast cancer."
Frost & Sullivan's recent analysis, Digital Pathology: Roadmap to the Future of Medical Diagnosis, covers the solutions of digital whole slide scanning, digital imaging solutions, and digital data repository. The study identifies technology advancements, applications, and potential, as well as presents the most successful business models and strategies currently dominating the market.
For further information on this analysis, please visit: http://frost.ly/37w
"Hospitals and diagnostic labs will be the largest adopters of digital pathology over the next decade," noted Jayakumar. "Technology innovators can ensure greater commercialization by focusing on improving cost optimization for end users through pay-per-use or Software-as-a-Service (SaaS) models. Additionally, they could map service gaps, expand product portfolios, and use the information obtained from clinical data to develop cutting-edge solutions."
A few highlighted growth opportunities for digital pathology-enabling technology companies within this analysis include:
Digital Pathology: Roadmap to the Future of Medical Diagnosis is part of Frost & Sullivan's global Medical Devices & Imaging Growth Partnership Service program.
Frost & Sullivan's global TechVision practice is focused on innovation, disruption and convergence and provides a variety of technology-based newsletters and research services as well as growth consulting services. Its premier offering, the Top 50 Technologies program, identifies and evaluates the most valuable emerging and disruptive technologies enabling products with near-term potential. A unique feature of the TechVision program is an annual selection of 50 technologies that can generate convergence scenarios, possibly disrupt existing business models, and drive transformational growth. View a summary of our TechVision program by clicking on the following link: http://ifrost.frost.com/TechVision_Demo.
About Frost & Sullivan
For over five decades, Frost & Sullivan has become world-renowned for its role in helping investors, corporate leaders and governments navigate economic changes and identify disruptive technologies, Mega Trends, new business models and companies to action, resulting in a continuous flow of growth opportunities to drive future success. Contact us: Start the discussion.
Digital Pathology: Roadmap to the Future of Medical Diagnosis
T: +1 210 348 10 12
T: +54 11 4778 3540